Journal article
Should sodium-glucose co-transporter-2 inhibitors be considered as first-line oral therapy for people with type 2 diabetes?
K Khunti, S Seidu, MJ Davies
Diabetes Obesity and Metabolism | WILEY | Published : 2019
DOI: 10.1111/dom.13518
Grants
Funding Acknowledgements
The authors acknowledge the support from the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care - East Midlands (NIHR CLAHRC - EM) and the NIHR Leicester, Biomedical Research Centre.